Get the Stockscreener App
1.69
24.55%
-0.55
Pre-market:
1.70
0.01
+0.59%
Compass Therapeutics Inc stock is traded at $1.69, with a volume of 5.69M.
It is down -24.55% in the last 24 hours and down -41.72% over the past month.
See More
Previous Close:
$2.24
Open:
$2.35
24h Volume:
5.69M
Relative Volume:
3.06
Market Cap:
$309.75M
Revenue:
-
Net Income/Loss:
$-45.44M
P/E Ratio:
-4.8286
EPS:
-0.35
Net Cash Flow:
$-42.28M
1W Performance:
-17.16%
1M Performance:
-41.72%
6M Performance:
-11.98%
1Y Performance:
-6.11%
1-Day Range:
$1.67
$2.435
1-Week Range:
$1.33
$2.435
52-Week Range:
$0.765
$4.08
Compass Therapeutics Inc Stock (CMPX) Company Profile
Name
Compass Therapeutics Inc
Sector
Industry
Phone
617-500-8099
Address
80 GUEST STREET, BOSTON
Compare CMPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
1.69 | 309.75M | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Initiated | Guggenheim | Buy |
| Feb-19-25 | Initiated | Piper Sandler | Overweight |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-15-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-31-23 | Initiated | Jefferies | Buy |
| Jan-27-23 | Initiated | Stifel | Buy |
| May-23-22 | Resumed | H.C. Wainwright | Buy |
| Mar-15-22 | Initiated | Ladenburg Thalmann | Buy |
| Jan-19-22 | Initiated | B. Riley Securities | Buy |
| Dec-22-21 | Initiated | Raymond James | Outperform |
| Dec-20-21 | Initiated | SVB Leerink | Outperform |
| Dec-15-21 | Initiated | Wedbush | Outperform |
View All
Compass Therapeutics Inc Stock (CMPX) Latest News
Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - The Manila Times
Leerink Partners Upgrades Compass Therapeutics (CMPX) - Nasdaq
Compass Therapeutics rises on trial win for biliary tract cancer therapy - MSN
Leerink raises Compass Therapeutics stock rating, PT to $6 from $4 - Investing.com
Compass Therapeutics And 2 More Compelling Penny Stocks - Yahoo Finance
Compass Therapeutics Target of Unusually Large Options Trading (NASDAQ:CMPX) - Defense World
Compass Therapeutics (NASDAQ:CMPX) Receives “Buy” Rating from D. Boral Capital - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Compass Therapeutics (NASDAQ:CMPX) Given Outperform Rating at Wedbush - Defense World
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing - GlobeNewswire
Compass Therapeutics price target raised to $11 from $10 at Stifel - MSN
Small Cap Compass Therapeutics Shares Positive Primary Goal Data From Pivotal Cancer Drug Study For Biliary Tract Cancer - Yahoo
Clinical Breakthrough Propels Compass Therapeutics (CMPX) Stock Higher - Stocks Telegraph
Compass Therapeutics Reports Positive Phase 2/3 Trial Results For Tovecimig - Nasdaq
Compass Therapeutics touts trial success in biliary tract cancer, but more data are needed - Endpoints News
Compass Therapeutics stock down amid trial win (CMPX:NASDAQ) - Seeking Alpha
Compass Therapeutics falls; brokerage says cancer drug trial data underwhelms - TradingView
Compass Therapeutics Says its Ongoing Biliary Tract Cancer Combination Drug Trial Indicates Statistically Significant Overall Response Rate - MarketScreener
Compass Therapeutics stock rises on trial win (CMPX:NASDAQ) - Seeking Alpha
Compass Therapeutics Reports Positive Phase 2/3 Trial Results - TipRanks
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer - The Manila Times
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Compass Therapeutics to Host Webcast Highlighting Top-Line - GlobeNewswire
Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer - The Manila Times
Compass Therapeutics, Inc.'s (NASDAQ:CMPX) market cap decline of US$44m may not have as much of an impact on institutional owners after a year of 0.5% returns - simplywall.st
Is Compass Therapeutics (CMPX) The Hot Biotech Stock Under $5? - Yahoo
Connor Clark & Lunn Investment Management Ltd. Trims Stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
[Top 3] Best Biotech Penny Stocks to Buy in 2025Finbold - Finbold - Finance in Bold
10 Hot Biotech Stocks Under $5 - Insider Monkey
With 42% stake, Compass Therapeutics, Inc. (NASDAQ:CMPX) seems to have captured institutional investors' interest - Yahoo Canada Finance
Gallbladder Neoplasms Treatment Market Size in the 7MM - openPR
Compass Therapeutics (CMPX) Projected to Post Earnings on Thursday - Defense World
Rubicon Technology (NASDAQ:RBCN) Now Covered by Analysts at StockNews.com - Defense World
Heron Therapeutics (NASDAQ:HRTX) Downgraded by StockNews.com to Hold - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Repligen (NASDAQ:RGEN) and Compass Therapeutics (NASDAQ:CMPX) Critical Review - Defense World
Research Analysts Issue Forecasts for CMPX Q1 Earnings - Defense World
Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025 - Insider Monkey
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
D. Boral Capital Reiterates "Buy" Rating for Compass Therapeutics (NASDAQ:CMPX) - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Compass Therapeutics shares rise on pipeline progress By Investing.com - Investing.com Canada
Compass Therapeutics shares rise on pipeline progress - Investing.com
Compass Therapeutics Reports 2024 Financial Results - TipRanks
Compass Therapeutics reports Q4 EPS (11c), consensus (9c) - TipRanks
Compass Therapeutics, Inc. SEC 10-K Report - TradingView
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire
D. Boral Capital Reiterates “Buy” Rating for Compass Therapeutics (NASDAQ:CMPX) - Defense World
Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Guggenheim - MarketBeat
Guggenheim Initiates Coverage of Compass Therapeutics (CMPX) with Buy Recommendation - Nasdaq
Compass stock gains amid Guggenheim buy rating - MSN
Compass Therapeutics Inc Stock (CMPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):